Table 1.
1. Crowdfunding should generally be explored before a P4 trial is considered, and it may be necessary to combine crowdfunding with P4 |
2. If the worst-off in society tend to benefit in the long run, a temporary inequality to those who cannot afford to participate in a P4 trial may be justified |
3. Research ethics committees must ensure that the design of trials is not compromised because of their P4 nature; specifically, all current trial standards regarding blinding, randomization, sample size and dose escalation must be met |
4. Extra safeguards against the therapeutic misconception must be put in place: those who “pay to play” are paying for participation in a trial that aims to provide social value through generalisable knowledge. They are paying for involvement in research, and any potential benefit to the patient/participant is merely an unlikely side effect |